CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Dinesh Patel

Chief Executive Officer, President, Secretary & Director, PROTAGONIST THERAPEUTICS INC

Search every verified Dinesh Patel interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Dinesh Patel, CEO of Protagonist Therapeutics, discussed the company's submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for rusfertide, an investigational hepcidin mimetic peptide designed to treat adults with polycythemia vera (PV), a rare condition characterized by excess red blood cells. In a January 2026 appearance, Patel described PV as a lifelong genetic condition affecting approximately 180,000 patients in the U.S., and noted that phase 3 data for rusfertide was selected for a plenary session at ASCO. He also outlined the company's strategy of partnering with larger pharmaceutical firms for blockbuster drugs while developing rare disease therapies independently, stating an intention to avoid diluting shareholder positions. In earlier interviews from 2020 to 2024, Patel recounted his career trajectory, including his upbringing in Zambia, his training as a medicinal chemist, and his experience founding and selling a previous company. He described Protagonist's focus on peptide drugs as an intermediate category between small molecules and biologics, and discussed the company's collaborations, including a partnership with Johnson & Johnson. Patel also spoke about his views on entrepreneurship, emphasizing the importance of developing products that address a clear need, and discussed his involvement in community service and charitable efforts, including support for an Indian cultural center in Salt Lake City.

Recent appearances

  • Submission of New Drug Application: Rusfertide for Polycythemia Vera

    February 17, 2026 · 📺 CheckRare

    Dinesh Patel, PhD, CEO of Protagonist Therapeutics, discusses the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV). PV is characterized by excess red blood cells in the bloodstream, increasing the risk for blood clots. Most cases of PV are acquired and occur more frequently in men than in women. The condition has been associated with genetic changes in the JAK2 and TET2 genes. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron…

    Watch on YouTube ↗

  • A Trailblazer in Biotechnology, Venture Capital and Community Service: Dr. Dinesh Patel

    January 11, 2024 · 📺 Beyond the Clouds: Edge-to-Edge Transformation

    I had the pleasure of speaking with Dr. Dinesh Patel, a renowned figure in Biotechnology, Venture Capital and Community Service. Dr. Patel's story is a fascinating journey of innovation, resilience, and community engagement, which began in Zambia, Central Africa. Born during the British colonial era in Zambia, Dr. Patel grew up in a society marked by segregation. He attended an Asian school, a reflection of the segregated educational system of the time. This early experience in a divided society laid the foundation for his perspectives on diversity and integration. Post-independence, Zambia s…

    Watch on YouTube ↗

  • From Humble Beginnings to Biotechnology: How Protagonist Therapeutics Makes Peptide Drugs

    September 15, 2023 · 📺 Beyond the Clouds: Edge-to-Edge Transformation

    Protagonist Therapeutics CEO, Dinesh Patel, talks about his work in the biotech industry, the challenges of developing peptide drugs, and the company's lead programs in polycythemia vera and psoriasis. Patel also talks about the company's collaboration with Johnson & Johnson, which has helped to accelerate the development of its pipeline. He says, Protagonist is poised to deliver innovative and life-changing peptide therapies to patients in need. Please Share & Subscribe on YouTube:    / @beyondtheclouds007   Subscribe to our newsletter on LinkedIn: https://lnkd.in/gc56VQ2M Themes: Protag…

    Watch on YouTube ↗

  • EPPIC SPOTLIGHT - Featuring Dinesh Patel, CEO of Protagonist Therapeutics. Hosted by Anu Deshpande.

    November 20, 2020 · 📺 Tech Talk With Anu - Anu Deshpande, Silicon Valley

    Dinesh Patel, CEO of Protagonist Therapeutics is featured in today's episode. During the interview he talks about what Protagonist Therapeutics does, major trends that he believes will affect the Pharma industry, globalization - the opportunities and challenges, great mentoring advice he has received over his career, the most important leadership lessons he has learned, his failures and his advice to emerging entrepreneurs.   / dinesh-patel-87928b9     / anu-deshpande-157813132   –––––––––––––––––––––––––––––– Upbeat Corporate by JP Bianchini https://jpbianchini.com Creative Commons — Attr…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →